From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need evaluate transcript. Question: Does management describe that company has recently crossed from candidate to approved/specified/listed/qualified/etc. inside buyers' purchasing systems, so future business can arrive without discrete selling event, and that status is new enough most volume ahead? Need identify in transcript. Transcript: Surmodics. They discuss Abbott agreement for SurVeil DCB commercialization rights. Abbott gets worldwide commercialization rights, Surmodics supplies product, collaborates on development, clinical trials, regulatory. Also options for below knee and AV fistula. This is a partnership/distribution agreement. Is that "approved, specified, listed, qualified" inside buyer's purchasing system? No, it's a commercialization agreement with a partner. Not a buyer-side pathway like formulary. Also they discuss products with regulatory clearances (Telemark microcatheter, .014/.018 balloons) and "progressing towards commercial agreements with several interested parties" who are reviewing products. They have clinical evaluations. But no mention of being placed on approved supplier lists, formularies, etc. They mention "commercial agreements" with partners, not buyer systems. Also "we will supply to Abbott" - that's a supply agreement, not access to end-user purchasing pathway. The question asks about company's products being inside buyers' own purchasing/reimbursement/formulary/specification systems. Not present. They mention regulatory clearances (FDA 510(k), CE Mark) but that's not buyer-side access. They mention "revenue from SurVeil agreement with Abbott" as license fee revenue, not product sales through a pathway. No mention of reimbursement codes, formularies, etc. So answer NO. Need ensure no other. They mention "commercialization strategy with potential distribution partners" - ordinary distribution agreements. Not enough. Also "we are progressing towards commercial agreements with several interested parties" - not yet. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.